Alexandria Hein

Pfizer expects to deliver 2.1 billion doses of its COVID-19 vaccine in 2021, with plans to manufacture a total of 3 billion by the end of 2021.

An expert panel unanimously voted that Biogen’s controversial Alzheimer’s drug does not provide more benefit to patients than supportive care.

Moderna will begin studying its COVID-19 vaccine in pregnant women, according to a posting on ClinicalTrials.gov.

The Food and Drug Administration’s acting commissioner, Janet Woodcock, is taking the highly unusual step of asking for a federal investigation of doctors within her own agency who met with the makers of an Alzheimer’s drug prior to the medicine’s FDA approval.

Merck announced Tuesday that the FDA approved an expanded label for Keytruda to treat patients with certain skin cancer that is not curable by surgery or radiation.

Eli Lilly announced Thursday that it had received the FDA’s Breakthrough Therapy designation for donanemab, an investigational antibody therapy for Alzheimer’s disease.

Novavax’s CEO said he believes boosters will be the company’s “biggest market” in the U.S. once it receives regulatory approval for its COVID-19 vaccine.

Philips has issued a recall for select sleep apnea machines and ventilators over concerns that a foam component may disintegrate and be inhaled by the user possibly causing health issues including toxic and carcinogenic effects.

A New Jersey company was hit with $13,600 in proposed fines from the U.S. Department of Labor’s Occupational Safety and Health Administration (OSHA) following the COVID-19-related deaths of a husband and wife.